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Abstract In this population-based study, we evaluated the
impact of obesity on presentation, diagnosis and treatment of
breast cancer. Among all women diagnosed with invasive
breast cancer in the canton Geneva (Switzerland) between
2003 and 2005, we identified those with information on body
mass index (BMI) and categorized them into normal/under-
weight (BMI\25 kg/m2), overweight (BMI C–\30 kg/m2)
and obese (BMI C30 kg/m2) women. Using multivariate
logistic regression, we compared tumour, diagnosis and
treatment characteristics between groups. Obese women
presented significantly more often with stage III–IV disease
(adjusted odds ratio [ORadj]: 1.8, 95% CI: 1.0–3.3). Tumours
C1 cm and pN2-N3 lymph nodes were significantly more
often impalpable in obese than in normal/underweight
patients (ORadj 2.4, [1.1–5.3] and ORadj 5.1, [1.0–25.4],
respectively). Obese women were less likely to have under-
gone ultrasound (ORadj 0.5, [0.3–0.9]) and MRI (ORadj 0.3,
[0.1–0.6]) and were at increased risk of prolonged hospital
stay (ORadj 4.7, [2.0–10.9]). This study finds important
diagnostic and therapeutic differences between obese and
lean women, which may impair survival of obese women
with breast cancer. Specific strategies are needed to optimize
the care of obese women with or at risk of breast cancer.
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Introduction
The relationship between obesity and breast cancer is com-
plex. Most epidemiological studies show that various mea-
sures of obesity are associated with a significant increase in
the risk of post-menopausal breast cancer [1, 2], while an
inverse relationship exists for pre-menopausal women [3].
There is accumulating evidence that obesity is associated
with adverse overall and disease-free survival for both pre-
and post-menopausal breast cancers [1, 4–6]. More advanced
stage at diagnosis [7], unfavourable tumour characteristics
[8] and suboptimal local and systemic treatment [9] have
been suggested to contribute to this detrimental prognosis.
This study was presented at the 6th European Breast Cancer
Conference; April 16–18, 2008; Berlin, Germany.
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Because of the increasing prevalence of obesity, in
combination with the high rates of breast cancer world-
wide, it is crucial to better understand the mechanisms
behind the impaired outcome of breast cancer associated
with obesity. In this population-based study, we assessed
the impact of obesity on presentation, diagnosis and
treatment of breast cancer in routine health care setting.
Materials and methods
We used data of the Geneva Cancer Registry, which records
all incident cancers occurring in the population of the
canton Geneva in Switzerland. Information is considered
accurate, as attested by the low percentage (\2%) of cases
registered by death certificate only [10]. Trained registrars
systematically collect information from various sources and
abstract data from medical files of all hospitals, private
practitioners and pathology laboratories in the canton.
Physicians regularly receive questionnaires to complete
missing data. Recorded data include sociodemographic
variables, tumour characteristics, stage at diagnosis and
treatment received within the first 6 months after diagnosis.
Since 2003, additional information, including body mea-
surements, was collected in the context of a larger research
of the Swiss Association of Cancer Registries, investigating
the pattern for breast cancer care in Switzerland.
For the purpose of our study, we identified all women
resident in the canton of Geneva (Switzerland) diagnosed
with histologically confirmed invasive breast cancer
between 1 January 2003 and 31 December 2005 (n = 1,110).
We excluded women with breast cancer detected at autopsy
(n = 5). Weight and height were retrieved from the medical
files and available for 460 out of 1,110 cases (41%).
These 460 individuals study cohort is representative of
the population-based sample in terms of patient and tumour
characteristics, except for the type of health insurance;
since height and weight were more often recorded or
retrieved in the file of patients treated in the public hospital,
72% of the women had basic health insurance in the study
cohort compared with 52% in the population-based one.
We recorded weight measured within 6 months after
diagnosis. The body mass index (BMI) was calculated as
the weight divided by the square metre of the height and
was further categorized according to the WHO criteria:
normal/underweight (BMI \25 kg/m2), overweight (BMI
C25–\30 kg/m2) and obese (BMI C30 kg/m2) [11].
Patient and tumour characteristics
Socioeconomic status was based on woman’s most recent
occupation or, when missing, that of the spouse and was
categorized as high (executives and administrators), middle
(non-manual employees), low (manual employees, skilled
and unskilled workers) and unknown. Health insurance
coverage was classified as basic versus private and marital
status as married versus unmarried. Familial risk was cat-
egorized as high (at least one-first-degree relative with
breast or ovarian cancer diagnosed before the age of
50 years), low (no affected first- or second-degree relatives
with breast or ovarian cancer), moderate (all other known
family histories) and unknown.
For staging, we used the pathological tumour node
metastasis (pTNM) classification system, or, when not
available, the clinical tumour node metastasis (cTNM)
classification. [12] Stage was classified as stage I (T0/T1
and N0), stage II (T0/T1 and N1, or T2 and N0/N1, or T3/
N0), stage III (T0/T1/T2 and N2, or T3 and N1/N2, or T4
and any N, or any T and N3), stage IV (any T, any N, M1),
unknown and further categorized as stage I/II versus III/IV.
We also recorded pathological tumour size (in millimetres)
and palpability of tumour and axillary lymph nodes (pal-
pable [cT1-4 or cN1-4] versus non-palpable [cT0 or cN0]).
Histological subtype was categorized as ductal (ICD-O
8500), lobular (ICD-O 8520 and 8522) and other [13].
Tumour differentiation was classified as good, moderate,
poor and unknown. Presence of an in situ component was
recorded and classified as present or absent, lymphovas-
cular invasion and multicentricity as yes versus no.
Oestrogen receptor [ER] and progesterone receptor [PR]
status were determined by standard immunohistochemical
reaction. Tumours expressing hormone receptors in \10%
of the cells were considered receptor negative and those
expressing receptors in C10% as receptor positive. ER and
PR status was regrouped as ER?/PR?, ER?/PR-, ER-/
PR?, ER-/PR- and unknown. HER-2 expression was
recorded as amplified or not, based on immunohisto-
chemistry or on the HER-2 gene amplification test by
fluorescence in situ hybridization.
Diagnostic and treatment characteristics
We categorized method of tumour detection into screening
(opportunistic or organized screening mammography,
ultrasound or clinical periodic breast examination), breast
self-examination, tumour symptoms (nipple discharge,
peau d’orange) and fortuitous discovery (during workup of
another unrelated illness). Use of mammography, ultra-
sound and magnetic resonance imaging (MRI) was coded
as performed versus not performed.
For loco-regional treatment, we classified surgery as
breast-conserving surgery, mastectomy and not performed.
Margins for invasive and in situ components were extrac-
ted from pathology reports (positive margins, margins of
\1 mm, 1–10 mm,[10 mm). Sentinel lymph node biopsy
and axillary dissection were classified as performed versus
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not performed. Radiotherapy was coded as yes versus no.
With the collected dates of hospitalisation, we computed
the number of days spent in hospital for the first surgical
intervention and categorized it in \5 days, 6–10 days and
[10 days.
Systemic therapies (hormone therapy, chemotherapy
and trastuzumab) were categorized as administered versus
not administered.
Statistics
Chi-square test was used to compare patient, tumour,
diagnosis and treatment characteristics between normal/
underweight (BMI\25 kg/m2), overweight (BMI C25 and
\30 kg/m2) and obese women (BMI C30 kg/m2).
In order to maximize the effect of obesity, we compared
obese women (BMI C30, n = 86) with normal/under-
weight women (BMI \25, n = 252), and a total of over-
weight women (n = 123, 26.7%) were excluded from
further analysis.
With univariate logistic regression analysis, we identi-
fied which covariates were significantly correlated with
obesity. Then, we performed different multivariate logistic
regression analyses, each model having its specific vari-
ables of adjustment. Models were fitted using maximum
likelihood method [14]. To identify tumour characteristics
significantly and independently associated with obesity, we
adjusted for age and health insurance status. Since socio-
economic status was strongly correlated to the type of
health insurance, we did not include it in adjusted analysis
in order to avoid colinearity. To assess the impact of
obesity on diagnosis and treatment of breast cancer, we
adjusted for demographic, tumour, diagnosis and treatment
covariates associated with obesity.
We performed stratified analysis addressing tumour and
lymph node palpability according, respectively, to histo-
logical tumour size and lymph node involvement, ER and
PR status according to menopausal status and stage
according to method of detection.
Two-tailed tests were used and statistical significance
was defined at P \ 0.05. Statistical analysis was performed
with SPSS software 15.0 version (SPSS, Inc., Chicago, IL).
Results
Patient and tumour characteristics
Among the 460 women included in the study, 252 (55%)
were considered as normal/underweight, 122 (26%) as
overweight and 86 (19%) as obese. Obese women were
significantly more often of low socioeconomic status and
had more often only basic health insurance compared with
normal/underweight women (Table 1). Obese (21%) and
overweight (24%) women tended to be less often in the
pre-menopause than normal/underweight women (31%).
Presence of a positive family history was not different
across BMI categories, neither were nationality, country of
birth and civil status (results not shown).
Obese women were nearly twice as likely to present
with advanced stage (stage III/IV) at diagnosis compared
with normal/underweight women (adjusted OR [ORadj]:
1.8, 95% CI: 1.0–3.3) (Table 2). Among women who
detected their tumour by means of self-examination, 40%
of obese against 20% of normal/underweight women had
stage III/IV disease (ORadj: 2.4, 95% CI: 1.0–5.9). Among
women with screen-detected tumours, 6% of obese and 4%
of lean women presented with stage III/IV disease (ORadj:
2.1, 95% CI: 0.3–13.7).
There was no significant difference in histological type,
differentiation, multicentricity, lymphovascular invasion
and presence of in situ component between obese and nor-
mal/underweight women (Table 3). Obese women tended to
have more often ER?/PR? and less often ER?/PR-
Table 1 Patient characteristics and associated P value chi-square test
according to the BMI
BMI P
chi-square
\25
N = 252
(%)
25 to \30
N = 122
(%)
C30
N = 86
(%)
Age (years)
[70 59 (23) 36 (29) 25 (29) 0.264
50–70 116 (46) 57 (47) 44 (51)
\50 77 (31) 29 (24) 17 (20)
Socioeconomic status
Middle 131 (52) 52 (43) 36 (42) 0.000
High 44 (18) 12 (10) 4 (5)
Low 43 (17) 38 (31) 23 (27)
Unknown 34 (13) 20 (16) 23 (26)
Health insurance
Basic 170 (68) 95 (78) 70 (81) 0.015
Private 82 (32) 27 (22) 16 (19)
Menopausal status
Post-menopause 171 (68) 93 (76) 68 (79) 0.090
Pre-menopause 79 (31) 29 (24) 18 (21)
Unknown 2 (1) 0 (0) 0 (0)
Family history
High 16 (6) 11 (9) 5 (6) 0.902
Middle 65 (26) 30 (25) 23 (27)
Low 158 (63) 79 (65) 53 (62)
Unknown 13 (5) 2 (1) 5 (5)
BMI body mass index
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tumours when compared with normal/underweight women
(ORadj: 0.4, 95% CI: 0.2–1.0). No significant difference was
found for ER and HER-2 status (results not shown).
Diagnosis and treatment characteristics
There was no significant difference in method of tumour
detection between obese and non-obese women (Table 4).
Diagnostic workup of obese women included significantly
less often ultrasound (ORadj: 0.5, 95% CI: 0.3–0.9) or MRI
(ORadj: 0.3, 95% CI: 0.1–0.6).
Overall, palpability of the primary tumour and of axil-
lary lymph nodes was comparable between the three
groups. However, after stratification by tumour size,
tumours larger than 1 cm were more frequently impalpable
in obese women (22%) than in normal/underweight women
(12%) (ORadj: 2.4, 95% CI: 1.1–5.3). Similarly, in obese
women with extensive axillary involvement (pN2-3),
axillary nodes were more often impalpable than in normal/
underweight women (54 vs. 19%, respectively; ORadj: 5.1,
95% CI: 1.0–25.4).
Compared with normal/underweight women, obese
women underwent significantly less often mastectomy
(ORadj: 0.3, 95% CI: 0.2–0.7) (Table 5). In addition, they
had less often narrow margins (\10 mm) after their first
surgical intervention, both for invasive (ORadj: 0.3, 95% CI:
0.1–0.5) and in situ components (ORadj: 0.2, 95% CI: 0.1–
0.5). There was no significant difference in use of sentinel
lymph node biopsy, axillary dissection or administration of
radiotherapy after breast-conserving surgery.
Obese and overweight women had a higher risk of pro-
longed hospital stay after surgery: 67% of obese and 66% of
overweight women were hospitalized for more than 5 days
compared with 46% of normal/underweight women
(P = 0.019). After correction for health insurance type,
age, stage and type of surgery, the risk of prolonged hospital
stay remained significantly increased for obese women
versus normal/underweight women: ORadj of 4.5 (95% CI:
1.9–10.8) for a stay of more than 5 days and ORadj of 13.3
(95% CI: 2.3–78.0) for a stay of more than 10 days.
Hormone therapy, chemotherapy and trastuzumab were
equally prescribed between the two groups (results not
shown).
Discussion
This population-based study shows that obesity affects
presentation, diagnostic assessment and management of
obese women with breast cancer. Notably, they present
with more advanced stage at diagnosis and encounter more
difficulties in clinical detection of primary tumours and
enlarged axillary lymph nodes. In addition, diagnostic
workup of obese and overweight women includes less often
ultrasound and MRI. Finally, obese women are at increased
risk of prolonged hospital stay.
Table 2 Relationship between
BMI and stage at diagnosis,
associated P value chi-square
test and odds ratio of obese vs.
normal/underweight women
BMI body mass index; CI
confidence interval; OR odds
ratio; Ref reference
* P \ 0.05;  0.07 \ P [ 0.05
a OR adjusted for age and
health insurance type
BMI P chi-square OR multi-adjusted
for obese vs. normal/
underweight (95% CI)a\25
N = 252 (%)
25 to \30
N = 122 (%)
C30
N = 86 (%)
Stage at diagnosis
I 111 (44) 47 (38) 29 (34) 0.288 1 Ref.
II 98 (39) 54 (44) 31 (36) 0.9 (0.5–1.8)
III 28 (11) 13 (11) 16 (19) 2.1 (0.9–5.2)
IV 11 (4) 7 (6) 8 (9) 2.5 (0.8–7.3)
Unknown 4 (2) 1 (1) 2 (2) – –
Stage in two categories
I/II 209 (83) 101 (83) 60 (70) 0.026 1 Ref.
III/IV 39 (15) 20 (16) 24 (28) 1.8 (1.0–3.3)*
Unknown 4 (2) 1 (1) 2 (2) – –
For cancer detected by self-examination
I/II 78 (80) 32 (82) 21 (58) 0.024 1 Ref.
III/IV 19 (19) 6 (16) 14 (39) 2.4 (1.0–5.9)
Unknown 1 (1) 1 (2) 1 (3) – –
For cancer detected by screening
I/II 101 (96) 54 (93) 30 (91) 0.660 1 Ref.
III/IV 4 (4) 4 (7) 2 (6) 2.1 (0.3–13.7)
Unknown 0 (0) 0 (0) 1 (3) – –
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The presence of a positive association between
advanced stage at diagnosis and obesity is corroborated by
several studies [5, 15–19].
One explanation could be that various biological factors
related to obesity stimulate tumour progression. The high
concentration of bioavailable oestrogen due to aromatiza-
tion of circulating androgens to oestrogen in adipose tissues
may have a mitogenic effect on breast cancer cells of obese
women with hormone-dependent tumours [20]. Some
studies have reported that obesity has a stronger negative
impact on breast cancer prognosis in patients with hormone
receptor positive tumours [21, 22]. In accordance with
several prospective [23–25] and case–control studies [26,
27], we found that obese women tended to have more often
ER?/PR? and less often ER?/PR- tumours compared
with normal/underweight women. Higher PR expression in
obese women was reported previously [25, 28, 29], and
could be an effect of the ER processing stimulation by
higher concentration of bioactive oestrogen [30].
Other hormonal and biological processes associated
with obesity, such as insulin-like growth factors, cytokines
and leptin could also be related to tumour cell proliferation
in obese women [31, 32]. A recent study among patients
with resected colorectal cancer showed that higher levels of
Table 3 Tumour
characteristics, associated P
value chi-square test according
to BMI and odds ratio of obese
vs. normal/underweight women
BMI body mass index; CI
confidence interval; ER
oestrogen receptors; Her-2
human epidermal growth factor
receptor 2; NA not applicable;
OR odds ratio; PR progesterone
receptors; Ref reference
* P \ 0.05;  0.07 \ P [ 0.05
a OR adjusted for age and
health insurance type
BMI P chi-square OR multi-adjusted
for obese vs. normal/
underweight (95% CI)a\25
N = 252 (%)
25 to \30
N = 122 (%)
C30
N = 86 (%)
Differentiation
Good 60 (24) 33 (27) 21 (25) 0.344 1 Ref.
Moderate 148 (59) 57 (47) 51 (59) 0.9 (0.5–1.8)
Poor 37 (14) 28 (23) 12 (14) 1.1 (0.5–2.5)
Unknown 7 (3) 4 (3) 2 (2) – –
Multicentricity
No 162 (64) 73 (60) 57 (66) 0.738 1 Ref.
Yes 66 (26) 37 (30) 19 (22) 1.2 (0.7–2.1)
Unknown 24 (10) 12 (10) 10 (12) – –
Lymphatic invasion
No 157 (62) 80 (66) 54 (63) 0.484 1 Ref.
Yes 25 (10) 17 (14) 8 (9) 1.0 (0.4–2.6)
Unknown 56 (28) 25 (20) 24 (28) – –
In situ component
No 66 (26) 32 (61) 27 (32) 0.080 1 Ref.
Yes 153 (61) 74 (26) 39 (45) 0.7 (0.4–1.3)
Unknown 33 (13) 16 (13) 20 (23) – –
Receptor status
ER/PR
ER?/PR? 170 (67) 84 (69) 66 (77) 0.213 1 Ref.
ER?/PR- 41 (16) 16 (13) 7 (8) 0.4 (0.2–1.0)
ER-/PR- 37 (15) 21 (17) 12 (14) 0.9 (0.4–1.8)
ER-/PR? 2 (1) 1 (1) 0 (0) NA
Unknown 2 (1) 0 (0) 1 (1) – –
PR in post-menopausal patients
\10% 52 (30) 24 (26) 13 (19) 0.083 1 Ref.
10–50% 43 (25) 28 (30) 14 (21) 1.3 (0.6–3.1)
[50% 75 (44) 40 (43) 40 (59) 2.1 (1.0–4.4)*
Unknown 1 (1) 1 (1) 1 (1) – –
ER in post-menopausal patients
\10% 23 (13) 11 (12) 7 (10) 0.874 1 Ref.
10–50% 12 (7) 7 (7) 3 (4) 0.9 (0.2–4.3)
[50% 135 (79) 74 (80) 57 (84) 1.5 (0.6–3.7)
Unknown 1 (1) 1 (1) 1 (2) – –
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Table 4 Diagnostic
characteristics, associated P
value chi-square test according
to BMI and odds ratio of obese
vs. normal/underweight women
BCS breast-conserving surgery;
BMI body mass index; CI
confidence interval; LN lymph
node; MRI magnetic resonance
imaging; OR odds ratio; Ref
reference
* P \ 0.05, ** P \ 0.01
a OR adjusted for age and
health insurance type
b OR adjusted for age, health
insurance type and stage
BMI P chi-square OR multi-adjusted
for obese vs. normal/
underweight (95% CI)\25
N = 252 (%)
25 to \30
N = 122 (%)
C30
N = 86 (%)
Method of detection
Self-examination 98 (39) 39 (32) 36 (42) 0.878 1 Ref.
Screening 105 (41) 58 (47) 33 (38) 1.0b (0.5–1.8)
Symptoms 37 (15) 18 (15) 14 (16) 0.9b (0.4–1.9)
Fortuitous 10 (4) 6 (5) 3 (4) 0.9b (0.2–3.7)
Unknown 2 (1) 1 (1) 0 (0) – –
Radiological examination
Mammography 0.684
Not performed 23 (9) 8 (6) 10 (12) 1 Ref.
Performed 227 (90) 113 (93) 76 (88) 0.7b (0.3–1.5)
Unknown 2 (1) 1 (1) 0 (0) – –
Ultrasound
Not performed 46 (18) 20 (16) 26 (30) 0.029 1 Ref.
Performed 206 (82) 102 (84) 60 (70) 0.5b (0.3–0.9)*
MRI
Not performed 168 (66) 94 (77) 77 (90) 0.001 1 Ref.
Performed 83 (33) 28 (23) 9 (10) 0.3b (0.1–0.6)**
Unknown 1 (1) 0 (0) 0 (0) – –
Clinical examination
Palpability of primary tumour
Palpable 191 (76) 96 (79) 62 (72) 0.762 1 Ref.
Impalpable 41 (16) 19 (16) 18 (21) 1.2a (0.6–2.1)
Unknown 20 (8) 7 (5) 6 (7) – –
Palpability of primary tumour according to its size
\1 cm
Palpable 28 (53) 11 (61) 4 (45) 0.426 1 Ref.
Impalpable 20 (38) 7 (39) 3 (33) 1.3a (0.2–7.4)
Unknown 6 (9) 0 (0) 2 (22) – –
C1 cm
Palpable 134 (80) 69 (80) 45 (73) 0.254 1 Ref.
Impalpable 19 (12) 11 (13) 14 (22) 2.4a (1.1–5.3)*
Unknown 14 (8) 6 (7) 4 (5) – –
Palpability of lymph nodes (LN)
Palpable 59 (23) 34 (28) 18 (21) 0.146 1 Ref.
Impalpable 187 (74) 86 (70) 62 (72) 1.2a (0.6–2.1)
Unknown 6 (3) 2 (2) 6 (7) – –
Palpability of LN according to LN involvement
pN1
Palpable 19 (32) 9 (27) 7 (39) 0.152 1 Ref.
Impalpable 38 (65) 23 (70) 8 (44) 0.5a (0.2–1.7)
Unknown 2 (3) 1 (3) 3 (17) – –
pN2-N3
Palpable 17 (81) 6 (75) 5 (46) 0.108 1 Ref.
Impalpable 4 (19) 2 (25) 6 (54) 5.1a (1.0–25.4)*
Unknown 0 (0) 0 (0) 0 (0) – –
190 Breast Cancer Res Treat (2010) 120:185–193
123
insulin and lower levels insulin-like growth factor binding
protein were associated with increased mortality, indicating
that these factors could be potential mediators of an asso-
ciation between life style factors and mortality after colo-
rectal cancer [33]. Obesity is often a marker for unhealthy
lifestyle habits, including excess saturated fat intake and
decreased level of physical activity, which are increasingly
being recognized as risk factors for adverse prognosis of
cancer [34].
Other mechanisms besides more aggressive tumour
behaviour may account for advanced stage and impaired
prognosis of obese women with breast cancer, in particular
differences in diagnosis and treatment.
We found the relationship between BMI and stage to be
associated with the method of cancer detection, obese
women having more often advanced stage when the tumour
was detected by self-examination. Similarly, in some
research [35], but not all [36], the association between
increased BMI and advanced stage was restricted to
women who self-detected their cancer, thus suggesting that
advanced stage may be due to delayed diagnosis because of
difficulties in detecting breast lumps in obese women. This
concept is supported by studies showing a positive asso-
ciation between breast size and stage of breast cancer [35–
37]. Likewise, we found that obese women with large
tumours or extensive lymph node involvement were
significantly more likely to have impalpable primary
tumours or axillary lymph nodes, which could lead to delay
in seeking medical attention.
Advanced stage at diagnosis could also be a conse-
quence of delayed medical consultation by obese women
because of embarrassment regarding their weight and
appearance [38–41]. Obese women have been shown to be
twice as likely to postpone doctor’s visit for more than
3 months after occurrence of first symptoms, resulting in
advanced stage of disease at presentation [42].
Another explanation for advanced stage at diagnosis
could be difference in radiological workup. Even though
similar proportions of obese and non-obese women were
detected by screening mammography in our study, obese
women underwent less often ultrasound and MRI as part of
their diagnostic workup. They may encounter negative
attitudes from health professionals, thus increasing the risk
of low compliance to radiological examination [38, 43].
Also, the lack of adapted radiological equipment (i.e. MRI)
for severely obese women could interfere with their diag-
nosis process.
This study also shows that obesity has a dual impact on
loco-regional treatment of breast cancer. On one hand,
obese women underwent less frequently mastectomy and
had more frequently large tumour-free margins, suggesting
it may be easier to achieve better oncological results and
Table 5 Loco-regional
treatment characteristics,
associated P value chi-square
test according to BMI and odds
ratio of obese vs. normal/
underweight women
BCS breast-conserving surgery;
BMI body mass index; CI
confidence interval; OR odds
ratio; Ref reference
* P \ 0.05, ** P \0.01,
*** P \ 0.001
a OR adjusted for age, health
insurance type and stage
b OR adjusted for age, health
insurance type, stage and type
of surgery
BMI P chi-square OR multi-adjusted for
obese vs. normal/
underweight (95% CI)\25
N = 252 (%)
25 to \30
N = 122 (%)
C30
N = 86 (%)
Surgery
BCS 166 (66) 89 (73) 63 (73) 0.046 1 Ref.
Mastectomy 69 (27) 25 (20) 12 (14) 0.3a (0.2–0.7)**
No surgery 17 (7) 8 (7) 11 (13) – –
Margin status
For invasive component
C10 mm 36 (15) 17 (15) 22 (29) 0.008 1 Ref.
\10 mm 187 (81) 86 (75) 47 (63) 0.3b (0.1–0.5)***
Unknown 9 (4) 11 (10) 6 (8) – –
For in situ component
C10 mm 20 (12) 10 (12) 12 (28) 0.009 1 Ref.
\10 mm 144 (83) 65 (78) 25 (58) 0.2b (0.1–0.5)***
Unknown 9 (5) 8 (10) 6 (14) – –
Length of hospital stay
\5 days 64 (54) 21 (34) 15 (33) 0.019 1 Ref.
6–10 days 50 (43) 37 (60) 26 (56) 4.5b (1.9–10.8)**
[10 days 4 (3) 4 (6) 5 (11) 13.3b (2.3–78.0)**
Radiotherapy
Performed 177 (70) 95 (78) 67 (78) 0.349 1 Ref.
Not performed 71 (28) 26 (21) 19 (22) 0.8b (0.3–2.4)
Unknown 4 (2) 1 (1) 0 (0) – –
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aesthetic outcome in surgery of larger breast. On the other
hand, obesity seems to have an unfavourable effect on the
recovery after breast cancer surgery, as obese women had
more often prolonged hospital stay. High BMI has been
identified as a significant and independent risk factor for
complications after breast or axillary surgery, such as
wound infections or lymphoedema [44–47]. In addition,
obese women may need more time to recover after surgery
due to complications linked to the higher prevalence of
comorbid conditions, which may impact on breast cancer
outcome by consequently postponing subsequent radio-
therapy and adjuvant treatments.
In accordance with another study [48], we did not find
any difference in access to radiotherapy following breast-
conserving surgery and the use of systemic treatment
between BMI categories. Nevertheless, we had no insight
into the quality and effectiveness of systemic treatments,
whereas obesity is increasingly reported to be associated
with a reduced dose for the first cycle of chemotherapy [49,
50], suggesting that physicians may use the ideal body
weight for the dose calculation to avoid overdosing and
toxicity. Recently, Litton et al. [5] showed that the rela-
tionship between higher BMI and a worse pathological
response rate after neoadjuvant chemotherapy was associ-
ated with worse overall survival.
We acknowledge that our study suffers from some
limitations. First of all, information on BMI was only
available for 41% of the population-based cohort. As
height and weight were better recorded at the public hos-
pitals, our study sample shows an over-representation of
women with basic health insurance. However, we believe
that, by adjusting for health insurance type, the association
between obesity and tumour diagnosis and treatment
characteristics is valid. Nevertheless, our study may have
overestimated the prevalence of obesity in Geneva breast
cancer patients, as women with basic health insurance had
a higher tendency towards obesity.
Also, by using a single measure of body weight, we did not
take weight changes during diagnosis and treatment process
into account. Even though the baseline body weight would be
more relevant when evaluating diagnosis aspects of the
disease, it may be less so when analyzing the pattern of care.
Finally, the small sample size prevents us for drawing
definite conclusion, and the results should be used to
generate hypothesis as well as need confirmation in larger
data sets.
In conclusion, our results emphasize that obesity has an
impact on diagnosis and treatment of breast cancer, which
may partly explain the impaired outcome associated with
obesity. These results indicate the need for more tailored
care of obese patients with breast cancer. Women and
clinicians have to be informed on the limited value of
breast (self-) examination associated with obesity. Also,
specific strategies should focus on improving access to
complete clinical and radiological workup, as well as on
solving medical and technical constraints for the treatment
of obese women with breast cancer.
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